Featured Press Releases

The Muscular Dystrophy Association and Forge Biologics announce AAV development

The Muscular Dystrophy Association and Forge Biologics announce AAV development

Kedrion Selected by Biotest to Distribute FDA-Approved Immunoglobulin Yimmugo® in the U.S

Kedrion Selected by Biotest to Distribute FDA-Approved Immunoglobulin Yimmugo® in the U.S

  • 01 Jul 2024

Kedrion Biopharma Inc. announced that it has established the framework for a long-term agreement...

Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

Nuvation Bio’s IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention

XOCOVA® Becomes First Oral Option for Post-Exposure COVID-19 Prevention

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Receives U.S. FDA Approval for an Additional Indication in Children and Adolescents Aged 2–17 Years at Increased Risk for Pneumococcal Disease

Bruker and Atinary Technologies Join Forces to Accelerate the Future of Self-Driving Laboratories

Bruker and Atinary Technologies Join Forces to Accelerate the Future of Self-Driving Laboratories

  • Bruker Corporation
  • 11 Aug 2026
Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

  • Neurolief Inc.
  • 11 Aug 2026
Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

Bruker Announces Majority Stake in MIMETAS to Accelerate Drug Discovery and Development Using Human Physiology-Relevant Models

  • Bruker Corporation
  • 10 Aug 2026
AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

  • Avantik
  • 10 Aug 2026
BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

BioVigil Reaches 1 Billion Hand Hygiene Opportunities, Marking a Major Milestone in Patient Safety and Infection Prevention

  • BioVigil
  • 10 Aug 2026
U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

  • Merck & Co., Inc
  • 06 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.